Biopharmaceutical profile of cerivastatin, a novel HMG-CoA reductase inhibitor

被引：5
|
作者：
Muck, W
Ochmann, K
Mazzu, A
Lettieri, J
机构：
[1] BAYER AG,CLIN PHARMACOL,D-5600 WUPPERTAL,GERMANY
[2] BAYER CORP,CLIN PHARMACOL,W HAVEN,CT
来源：
ATHEROSCLEROSIS | 1997年 / 134卷 / 1-2期
关键词：
D O I：
10.1016/S0021-9150(97)88701-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：130 / 130
页数：1
相关论文
共 50 条
  • [1] Biopharmaceutical profile of cerivastatin:: a novel HMG-CoA reductase inhibitor
    Mück, W
    Ochmann, K
    Mazzu, A
    Lettieri, J
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1999, 27 (03) : 107 - 114
  • [2] Cerivastatin, a novel HMG-CoA reductase inhibitor: Efficacy and tolerability
    Schmage, N
    Cagatay, M
    Park, SM
    Lommerzheim, A
    Schopen, U
    HERZ KREISLAUF, 2000, 32 (7-8): : 242 - 252
  • [3] Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor
    von Keutz, E
    Schlüter, G
    AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (4B): : 11J - 17J
  • [4] Cerivastatin (BAY w 6228):: A novel HMG-CoA reductase inhibitor
    Kuhlmann, J
    Mück, W
    Bischoff, H
    von Keutz, E
    Llewellyn, M
    CARDIOVASCULAR DRUG REVIEWS, 1998, 16 (03): : 236 - 263
  • [5] In vitro antitumor activity of cerivastatin, a novel and potent HMG-CoA reductase inhibitor
    Feleszko, W
    Mlynarczuk, I
    Nowis, D
    FEBS LETTERS, 2001, 503 (2-3) : 219 - 220
  • [6] Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor
    Bischoff, H
    Angerbauer, R
    Bender, J
    Bischoff, E
    Faggiotto, A
    Petzinna, D
    Pfitzner, J
    Porter, MC
    Schmidt, D
    Thomas, G
    ATHEROSCLEROSIS, 1997, 135 (01) : 119 - 130
  • [7] Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin
    Ritter, W
    Ochmann, K
    Muck, W
    Kuhlmann, J
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 355 (04) : 477 - 477
  • [8] Cerivastatin: the low-dose HMG-COA reductase inhibitor
    Tikkanen, MJ
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (01) : 161 - 166
  • [9] Cerivastatin approval expands HMG-CoA reductase inhibitor choices
    不详
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (16) : 1793 - 1793
  • [10] Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin
    Muck, W
    Ritter, W
    Ochmann, K
    Unger, S
    Ahr, G
    Wingender, W
    Kuhlmann, J
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1997, 35 (06) : 255 - 260
12345